ClinicalTrials.gg
CompletedNCT01844583Updated Mar 25, 2019Results posted

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

A Phase 1 interventional study of Alisertib and Esomeprazole in Solid Tumors and Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-25.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.

Enrollment
9th of 23
55 · median 36
Started
2013
with 4 others
Phase 1
12 of 26
none open now
Registered
11th of 26
by date

Among the 26 studies in Lymphoma by Takeda, this one is the 9th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 1, and was the 11th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lymphoma by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.

Read the detailed description

The drug tested in this study is called alisertib. Alisertib is being tested to assess the effect of a proton pump inhibitor and strong metabolic inducer on the PK of a single 50 mg dose of alisertib administered as enteric-coated tablets (ECTs).

The study enrolled 55 patients. Participants received either:

  • Esomeprazole 40 mg and Alisertib 50 mg
  • Rifampin 600 mg and Alisertib 50 mg

All participants were asked to take one tablet of alisertib either once or twice daily in all cycles. In Cycle 2, participants were asked to take alisertib plus either esomeprazole or rifampin.

This trial was conducted the United States. The overall time to participate in this study was 10 months. Participants made multiple visits to the clinic plus a final visit, 30 days after receiving their last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Solid Tumors
  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants 18 years or older
  • or cytologically confirmed and/or advanced solid tumors or lymphomas
  • (ECOG) performance status 0 or 1
  • Expected survival longer than 3 months from enrollment in the study
  • Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of or agree to abstain from heterosexual intercourse
  • Male participants who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse

Exclusion criteria

Exclusion Criteria:

  • Treatment with any anticancer therapy or any agents within 4 weeks before the first dose of alisertib

    - Known or intolerance to rifampin (for participants considered for the rifampin drug-drug interaction [DDI] group) or to esomeprazole (for participants considered for the esomeprazole DDI group)

  • Recurrent nausea and/or vomiting within 14 days before the first dose of alisertib, and known gastrointestinal (GI) abnormality or GI procedure that could interfere with or modify the oral absorption or tolerance of alisertib
  • Participants requiring treatment with enzyme inducers within 14 days before the first dose of alisertib and/or requiring the use of these medications during the study
  • A medical condition requiring use of pancreatic enzymes; or daily, chronic, or regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists
  • Participants requiring systemic anticoagulation (excluding low-dose aspirin, or low-dose anticoagulation to maintain patency of venous access devices).
  • Any cardiovascular condition
  • Female participants who are lactating or have a positive serum pregnancy test
  • Major surgery within the 14 days preceding the first dose of alisertib

    - Life-threatening or uncontrolled medical illness unrelated to cancer

  • Newly diagnosed or uncontrolled cancer-related central nervous system (CNS) disease
  • stem cell transplant within 3 months
  • Prior allogeneic bone marrow or other organ transplantation

    - Other severe acute or chronic medical or psychiatric condition

  • Known or suspected (HIV) positive or surface antigen-positive status, or known or suspected active infection

Please note there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Esomeprazole 40 mg + Alisertib 50 mg

    Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1. Esomeprazole, 40 mg, delayed-release capsules, orally, once daily on Days 1 to 10 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2. Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles).

    Drug: Alisertib · Drug: Esomeprazole

  • Experimental
    Rifampin 600 mg + Alisertib 50 mg

    Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1. Rifampin 600 mg, capsules, orally, once daily on Days 1 to 10 in Cycle 2 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2. Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles).

    Drug: Alisertib · Drug: Rifampin

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm

  2. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Esomeprazole

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm

  3. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence and Absence of Esomeprazole

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm

  4. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Esomeprazole

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm

  5. Terminal Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Esomeprazole

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm

  6. Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Rifampin

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm

  7. AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Rifampin

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm

  8. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence or Absence of Rifampin

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm

  9. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Rifampin

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm

  10. Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Rifampin

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm

  11. Change From the Time-matched Baseline in the Individually Corrected QTc Interval (QTcI)

    Time frame: Baseline, Days 1 and 10 multiple timepoints postdose (up to 24 hours) in Cycle 1

Secondary outcomes

  1. Change From the Time-matched Baseline in the Fridericia Correction of QTc (QTcF)

    Time frame: Baseline, Days 1 and 10 multiple timepoints postdose (up to 24 hours) in Cycle 1

  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: From the first dose through 30 days after administration of the last dose of study drug (up to 328 days)

07

Results

Posted Mar 25, 2019

Participant flow

Participants took part in the study at 6 investigative sites in the United States from 25 June 2013 to 06 September 2016. Data cut-off for primary analysis was 04 August 2014.

Participant flow — Overall Study
MilestoneEsomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mg
Started2629
Completed1819
Not completed810
Withdrew: Didn't complete dosing;pk/ecg assessment810

Outcome measures

PrimaryCmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
Reported as:
Mean · nmol/L
Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole
nmol/LAlisertib Without EsomeprazoleAlisertib With Esomeprazole
Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole1542.6 ± 357.191804.8 ± 571.89
Statistical analysis
  • Alisertib Without Esomeprazole vs Alisertib With Esomeprazole · Ls mean ratio: 1.14 · 90% CI 0.97 to 1.35Estimates for each PK parameter were obtained using a mixed effects model of log (PK parameter) with fixed terms for the esomeprazole effect and random terms for participants within sequence.
PrimaryAUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Esomeprazole
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
Reported as:
Mean · hr*nmol/L
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Esomeprazole
hr*nmol/LAlisertib Without EsomeprazoleAlisertib With Esomeprazole
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Esomeprazole20427.8 ± 6813.4625094.4 ± 5574.04
Statistical analysis
  • Alisertib Without Esomeprazole vs Alisertib With Esomeprazole · Ls mean ratio: 1.25 · 90% CI 1.08 to 1.45Estimates for each PK parameter were obtained using a mixed effects model of log (PK parameter) with fixed terms for the esomeprazole effect and random terms for participants within sequence.
PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence and Absence of Esomeprazole
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
Reported as:
Mean · hr*nmol/L
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence and Absence of Esomeprazole
hr*nmol/LAlisertib Without EsomeprazoleAlisertib With Esomeprazole
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence and Absence of Esomeprazole21371.4 ± 8138.5526612.5 ± 6626.40
Statistical analysis
  • Alisertib Without Esomeprazole vs Alisertib With Esomeprazole · Ls mean ratio: 1.28 · 90% CI 1.07 to 1.53Estimates for each PK parameter were obtained using a mixed effects model of log (PK parameter) with fixed terms for the esomeprazole effect and random terms for participants within sequence.
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Esomeprazole
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Esomeprazole
hoursAlisertib Without EsomeprazoleAlisertib With Esomeprazole
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Esomeprazole4.0 (2 to 8)3.0 (1 to 8)
PrimaryTerminal Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Esomeprazole
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
Reported as:
Mean · hours
Terminal Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Esomeprazole
hoursAlisertib Without EsomeprazoleAlisertib With Esomeprazole
Terminal Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Esomeprazole16.06 ± 5.39815.96 ± 5.234
PrimaryCmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Rifampin
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
Reported as:
Mean · nmol/L
Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Rifampin
nmol/LAlisertib Without RifampinAlisertib With Rifampin
Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Rifampin1561.4 ± 661.811581.5 ± 519.68
Statistical analysis
  • Alisertib Without Rifampin vs Alisertib With Rifampin · Ls mean ratio: 1.03 · 90% CI 0.84 to 1.26Estimates for each PK parameter were obtained using a mixed effects model of log (PK parameter) with fixed terms for the esomeprazole effect and random terms for participants within sequence.
PrimaryAUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Rifampin
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
Reported as:
Mean · hr*nmol/L
AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Rifampin
hr*nmol/LAlisertib Without RifampinAlisertib With Rifampin
AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Rifampin19732.0 ± 8489.249470.5 ± 2653.60
Statistical analysis
  • Alisertib Without Rifampin vs Alisertib With Rifampin · Ls mean ratio: 0.51 · 90% CI 0.41 to 0.62Estimates for each PK parameter were obtained using a mixed effects model of log (PK parameter) with fixed terms for the esomeprazole effect and random terms for participants within sequence.
PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence or Absence of Rifampin
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
Reported as:
Mean · hr*nmol/L
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence or Absence of Rifampin
hr*nmol/LAlisertib Without RifampinAlisertib With Rifampin
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence or Absence of Rifampin17258.3 ± 6163.608955.0 ± 2389.25
Statistical analysis
  • Alisertib Without Rifampin vs Alisertib With Rifampin · Ls mean ratio: 0.53 · 90% CI 0.41 to 0.70Estimates for each PK parameter were obtained using a mixed effects model of log (PK parameter) with fixed terms for the esomeprazole effect and random terms for participants within sequence.
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Rifampin
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Rifampin
hoursAlisertib Without RifampinAlisertib With Rifampin
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Rifampin4.0 (1 to 23)2.1 (1 to 6)
PrimaryPhase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Rifampin
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
Reported as:
Mean · hours
Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Rifampin
hoursAlisertib Without RifampinAlisertib With Rifampin
Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Rifampin16.30 ± 6.6088.17 ± 5.476
PrimaryChange From the Time-matched Baseline in the Individually Corrected QTc Interval (QTcI)
Time frame:
Baseline, Days 1 and 10 multiple timepoints postdose (up to 24 hours) in Cycle 1
Reported as:
Mean · milliseconds (msec)
Change From the Time-matched Baseline in the Individually Corrected QTc Interval (QTcI)
milliseconds (msec)Alisertib
Day 10, 0 hour postdose-2.2 (NA to 0.99)
Day 1, 0.5 hour postdose-3.7 (NA to -1.63)
Day 10, 0.5 hour postdose-5.4 (NA to -2.24)
Day 1, 1 hour postdose-4.5 (NA to -2.37)
Day 10, 1 hour postdose-3.5 (NA to -0.4)
Day 1, 2 hours postdose-4.0 (NA to -1.94)
Day 10, 2 hours postdose-1.6 (NA to 1.54)
Day 1, 3 hours postdose-2.5 (NA to -0.42)
Day 10, 3 hours postdose-2.3 (NA to 0.89)
Day 1, 4 hours postdose-1.2 (NA to 0.9)
Day 10, 4 hours postdose-1.2 (NA to 1.91)
Day 1, 6 hours postdose-0.9 (NA to 1.15)
Day 10, 6 hours postdose-3.5 (NA to -0.33)
Day 1, 8 hours postdose-0.5 (NA to 1.61)
Day 10, 8 hours postdose-0.4 (NA to 2.75)
Day 1, 10 hours postdose-1.5 (NA to 0.56)
Day 10, 10 hours postdose-2.4 (NA to 0.73)
Day 1, 24 hours postdose-3.3 (NA to -1.2)
SecondaryChange From the Time-matched Baseline in the Fridericia Correction of QTc (QTcF)
Time frame:
Baseline, Days 1 and 10 multiple timepoints postdose (up to 24 hours) in Cycle 1
Reported as:
Mean · milliseconds (msec)
Change From the Time-matched Baseline in the Fridericia Correction of QTc (QTcF)
milliseconds (msec)Alisertib
Day 10, 0 hour postdose-2.4 (NA to 0.7)
Day 1, 0.5 hour postdose-3.9 (NA to -1.8)
Day 10, 0.5 hour postdose-5.3 (NA to -2.19)
Day 1, 1 hour postdose-4.6 (NA to -2.54)
Day 10, 1 hour postdose-3.9 (NA to -0.76)
Day 1, 2 hours postdose-3.5 (NA to -1.51)
Day 10, 2 hours postdose-2.5 (NA to 0.63)
Day 1, 3 hours postdose-2.1 (NA to -0.09)
Day 10, 3 hours postdose-2.6 (NA to 0.55)
Day 1, 4 hours postdose0 (NA to 2.07)
Day 10, 4 hours postdose-1.3 (NA to 1.87)
Day 1, 6 hours postdose-0.5 (NA to 1.5)
Day 10, 6 hours postdose-4.1 (NA to -0.92)
Day 1, 8 hours postdose0 (NA to 2.1)
Day 10, 8 hours postdose-1.6 (NA to 1.54)
Day 1, 10 hours postdose-1.2 (NA to 0.9)
Day 10, 10 hours postdose-3.5 (NA to -0.3)
Day 1, 24 hours postdose-3.8 (NA to -1.72)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
From the first dose through 30 days after administration of the last dose of study drug (up to 328 days)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsEsomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mg
AEs2527
SAEs911

Adverse events

Collected over From the first dose through 30 days after administration of the last dose of study drug (up to 328 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole 40 mg + Alisertib 50 mg1/26 (3.8%)9/26 (34.6%)25/26 (96.2%)
Rifampin 600 mg + Alisertib 50 mg3/29 (10.3%)11/29 (37.9%)25/29 (86.2%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventEsomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mg
VomitingGastrointestinal disorders1/262/29
NauseaGastrointestinal disorders0/262/29
Deep vein thrombosisVascular disorders0/262/29
Abdominal painGastrointestinal disorders1/261/29
ColitisGastrointestinal disorders1/260/29
AscitesGastrointestinal disorders1/260/29
Urinary tract infectionInfections and infestations1/260/29
Septic shockInfections and infestations1/260/29
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/260/29
Cerebrovascular accidentNervous system disorders1/260/29
Most frequent other events
Showing 10 of 48
Most frequent other events
EventEsomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mg
DiarrhoeaGastrointestinal disorders15/264/29
AlopeciaSkin and subcutaneous tissue disorders14/266/29
FatigueGeneral disorders12/2610/29
StomatitisGastrointestinal disorders11/266/29
NeutropeniaBlood and lymphatic system disorders10/267/29
AnaemiaBlood and lymphatic system disorders7/268/29
VomitingGastrointestinal disorders7/265/29
NauseaGastrointestinal disorders7/264/29
Decreased appetiteMetabolism and nutrition disorders7/263/29
LeukopeniaBlood and lymphatic system disorders4/266/29

Baseline characteristics

The safety population included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Esomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mgTotal
Mean62.2 ± 6.9060.4 ± 10.5861.3 ± 8.99
Sex: Female, Male
Sex: Female, Male(Participants)Esomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mgTotal
Female142135
Male12820
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Esomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mgTotal
Hispanic or Latino347
Not Hispanic or Latino222446
Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Esomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mgTotal
White222648
Black or African American213
Native Hawaiian or Other Pacific Islander000
Asian000
American Indian or Alaska Native112
Other011
Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Esomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mgTotal
United States262955
Height
Height(cm)Esomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mgTotal
Mean166.6 ± 8.90164.8 ± 9.09165.7 ± 8.97
Weight
Weight(kg)Esomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mgTotal
Mean82.07 ± 20.76577.37 ± 33.80179.59 ± 28.242
Body Mass Index
Body Mass Index(kg/m^2)Esomeprazole 40 mg + Alisertib 50 mgRifampin 600 mg + Alisertib 50 mgTotal
Mean29.557 ± 7.278728.026 ± 9.417528.750 ± 8.4327
08

Study locations

7 sites
  • Sarasota, Florida, United States
  • St Louis, Missouri, United States
  • Oklahoma City, Oklahoma, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Madison, Wisconsin, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Aug 2014, 13 months.

Results were first posted in Mar 2019, 4 years 7 months after primary completion.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 13 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2013
First posted
May 1, 2013
StartActual
Jun 25, 2013
Primary completionActual
Aug 4, 2014
CompletionActual
Sep 6, 2016
Results first posted
Mar 25, 2019
Last update
Mar 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01844583
Responsible party
Sponsor
First posted
May 1, 2013
Start date
Jun 25, 2013
Primary completion
Aug 4, 2014
Completion
Sep 6, 2016
Results posted
Mar 25, 2019
Last update
Mar 25, 2019

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion